

DBCG

DANISH BREAST CANCER COOPERATIVE GROUP

INFORMATIONSBLAD NR 38

JUNI 2006

ADDENDUM I

DBCG's publikationsliste

Reference 1 – 193 se Informationsblad nr. 37, juni 2005, addendum I

194. Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. *Reproductive risk factors for breast cancer by receptor status, histology, laterality and location.* Int. J. Cancer **1999**; 81:49-55.
195. Wohlfahrt J, Melbye M. *Maternal Risk of Breast Cancer and Birth Characteristics of Offspring by Time Since Birth.* Epidemiology **1999**; 10(4):441-4.
196. Kroman N, Thorpe SM, Wohlfahrt J, Andersen KW, Mouridsen HT. *Variations in prognostic factors in primary breast cancer throughout the menstrual cycle.* Eur J Surg Oncol **2000**; 26:11-16.
197. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. *Factors influencing the effect of age on prognosis in breast cancer: population based study.* Br Med J **2000**; 320:474-9.
198. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. *Bør alle yngre mammacancerpatienter tilbydes adjuverende cytotoxisk kemoterapi?* Ugeskr Læg **2000**; 320:474-8.
199. Early Breast Cancer Trialists' Collaborative Group. *Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials.* Lancet **2000**; 355:1757-70.
200. Axelsson CK, Rank F, Blichert-Toft M, Mouridsen HT, Jensen MB on behalf of The Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen, Denmark. *Impact of Axillary Dissection on Staging and Regional Control in Breast Tumors ≤ 10 mm.* Acta Oncol **2000**; 39:283-89.
201. Blichert-Toft M. *Axillary Surgery in Breast Cancer Management. Background, Incidence and Extent of Nodal Spread, Extent of Surgery and Accurate Axillary Staging, Surgical Procedures.* Acta Oncol **2000**; 39:269-75.
202. Johansen J, Overgaard J, Blichert-Toft M, Overgaard M. *Treatment Morbidity Associated with the Management of the Axilla in Breast-Conserving Therapy.* Acta Oncol **2000**; 39:349-54.
203. Lauridsen MC, Tørsleff KR, Husted H, Erichsen C. *Physiotherapy treatment of late symptoms following surgical treatment of breast cancer.* The Breast **2000**; 9:45-51.
204. Rostgaard K, Holst H, Mouridsen HT, Lynge E. *Do clinical databases render population-based cancer registers obsolete? The example of breast cancer in Denmark.* Cancer Causes and Control **2000**; 11:669-74.
205. Ottesen Gyda Lolk, Graversen Hans Peder, Blichert-Toft Mogens, Christensen Ib Jarle, Andersen Johan A. *Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study.* Breast Cancer Research and Treatment **2000**; 62:197-210
206. Højris I, Andersen J, Overgaard M, Overgaard J. *Late Treatment-Related Morbidity in Breast Cancer Patients Randomized to Postmastectomy Radiotherapy and Systemic Treatment Versus Systemic Treatment Alone.* Acta Oncol **2000**; 39:355-72.
207. Wohlfahrt J, Melbye M. *Gender of offspring and long-term maternal breast cancer risk.* Br. J. Cancer. **2000**; 82(5):1070-2.

208. Kroman N. *Prognostic influence of age and reproductive factors in premenopausal breast cancer patients*. Doctoral Thesis. University of Copenhagen **2001**.
209. Rostgaard K, Mouridsen HT, Væth M, Holst H, Olesen KP, Lynge E. *A Modified Nottingham Prognostic Index for Breast Cancer Patients Diagnosed in Denmark 1978 - 1994*. *Acta Oncol* **2001**; 40: 838-43.
210. Voogd AC, Nielsen M, Peterse Johannes L, Blichert-Toft M, Bartelink H, Overgaard M, van Tienhoven G, Andersen KW, Sylvester RJ, van Dongen JA, for the Danish Breast Cancer Cooperative Group and the Breast Cancer Cooperative Group of the European Organisation for Research and Treatment of Cancer. *Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials*. *J Clin Oncol* **2001**; 19: 1688-97.
211. Bergthorsson JT, Ejlertsen B, Olsen JH, Nielsen KV, Barkardottir RB, Klausen S, Mouridsen HT, Winther K, Fenger K, Niebuhr A, Harboe TL, Niebuhr E. *BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age*. *J Med Genet* **2001**; 38:361-68.
212. Wohlfahrt J, Andersen PK, Mouridsen HT, Melbye M. *Risk of late-stage breast cancer after a childbirth*. *Am. J. Epidemiol.* **2001**; 153(11):1079-84.
213. Tange UB, Hirsch FR, Jensen MB, Olsen AH, Blichert-Toft M, Rank FE, Vejborg IMM, Mouridsen HT, soc.Lynge E. *Mammografiscreening i Københavns Kommune.Kliniske konsekvenser efter de første tre screeningsrunder*. *Ugeskr Læg* **2002**; 164: 1036-40.
214. Tange UB, Hirsch FR, Jensen MB, Olsen AH, Blichert-Toft M, Rank FE, Vejborg IMM, Mouridsen HT, Lynge E. *Mammografiscreening i Københavns Kommune.Populationsresultater fra de første tre screeningsrunder*. *Ugeskr Læg* **2002**; 164: 1048-52.
215. Blichert-Toft M, Ejlertsen B, Mouridsen H.T., Overgaard M. *Mammacancer*. *Ugeskr Læg* **2002**; 164: 3023-6.
216. Johansen J, Overgaard J, Rose C, Engholm S.Aa, Gadeberg C.C., Kjær M, Kamby C, Juul-Christensen J, Blichert-Toft M, Overgaard M, on behalf of the Danish Breast Cancer Cooperative Group (DBCG) and the DBCG Radiotherapy Committee. *Cosmetic Outcome and Breast Morbidity in Breast-Conserving Treatment*. *Acta Oncol* **2002**; 41: 369-80.
217. Offersen BV, Sørensen FB, Yilmaz M, Knoop A, Overgaard J. *Chalkley Estimates of Angiogenesis in Early Breast Cancer*. *Acta Oncol* **2002**; 41:695-703.
218. Tange U.B, Jensen M-B, Vejborg I.M.M, Rank F.E, Blichert-Toft M, Mouridsen H.T, Lynge E. *Clinical impact of introduction of mammography screening in a non-screening country*. *Scandinavian Journal of Surgery* 91: **2002**; 293-303.
219. Kroman N, Melbye M, Mouridsen H.T. *Prognostic influence of age at diagnosis in premenopausal breast cancer patients*. *Scandinavian Journal of Surgery* 91: **2002**; 305-8.

220. Blichert-Toft M., Smitten K.Von. *Aspects Of Breast Surgery*. Scand.J.of Surg. **2002**; 91:219-21.
221. Blichert-Toft M., Kroman N. *The Specialist Breast Unit and Breast Surgery as a Specialty*. Scand.J.of Surg. **2002**; 91: 227-31
222. Vejborg I., Olsen A.H., Jensen M-B., Rank F., Tange U.B., Lynge E. *Early outcome of mammography screening in Copenhagen 1991-99*. J Med Screen **2002**; 9:115-19.
223. Jensen AR, Overgaard J, Storm HH. *Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark*. Eur J Cancer Prevention **2002**; 11:359-64
224. Kroman N., Wohlfahrt J., Mouridsen HT, Melbye M. *Influence of tumor location on breast cancer prognosis*. Int.J.Cancer **2003**; 105: 542-45.
225. Celis JE, Gromov P, Gromova I, Moreira JMA, Cabezon T, Ambartsumian N, Grigorian M, Lukanidin E, Straten PT, Guldborg P, Bartkova J, Bartek J, Lukas J, Lukas C, Lykkesfeldt A, Jäättelä M, Roepstorff P, Bolund L, Ørntoft T, Brüner N, Overgaard J, Sandelin K, Blichert-Toft M, Mouridsen H, Rank FE. *Molecular and cellular Proteomics*. **2003**; 2:369-77.
226. Kroman N, Blichert-Toft M. *Long-term survival was similar after breast-conserving surgery or mastectomy for breast cancer*. Evidence-based Obstetrics and Gynecology **2003**; 5: 48-50.
227. Vejborg I, Friis E, Blichert-Toft M. *Brystkræft kan opdages i tide*. Scandinavian Health News, ISBN 87-7749-391-5, FADL's Forlag, København, Oktober, **2003**.
228. Vejborg I, Friis E, Blichert-toft M. *Brystkræft der opdages i tide kan helbredes*. Scandinavian Health News, ISBN 87-7749-416-4, FADL's Forlag, København, Oktober, **2003**.
229. Jensen AJ, Storm HH, Møller S, Overgaard J. *Validity and Representativity in the Danish Breast Cancer Cooperative Group*. Acta Oncol **2003**; 42:179-85
230. Jensen AJ, Garne JP, Storm HH, Ewertz M, Cold S, Alvegaard T, Overgaard J. *Stage and Survival in Breast Cancer Patients in Screened and Non-screened Danish and Swedish Populations*. Acta Oncologica **2003**; 42:701-09
231. Jensena AR, Ewertz M, Cold S, Storm HH, Overgaard J. *Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark*. Eur J of Cancer **2003**; 39:1783-93
232. Offersen BV, Sørensen FB, Knoop A, Overgaard J. *The prognostic relevance of estimates of proliferative activity in early breast cancer*. Histopathology **2003**; 43:573-82
233. Ejlertsen B, Højris I, Hansen s, Møholt K, Kristensen B, Mouridsen HT, Andersen J, Rose C, Kjær M. *Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group*. The Breast **2003**; 12:42-50
234. Hölmich LR, Mellekjær L, Gunnarsdóttir KA, Tange UB, Krag C, Møller S, McLaughlin JK, Olsen JK. *Stage of breast cancer at diagnosis among women*

- with cosmetic breast implants. *British Journal of Cancer* **2003**; 88, 832-38
235. Hjerl K, M.D., Ph.D., Andersen EW, Sc.D. Keiding N, Sc.D., Mouridsen HT, M.D., Dr. Med. Sci. Mortensen PB, M.D., Dr. Med.Sci. Jørgensen T, M.D., Dr. Med. Sci. *Depression as a Prognostic Factor for Breast Cancer Mortality. Psychosomatics* **2003**; 44:24-30
236. Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Blichert-Toft M, Melbye M. *Effect of Breast-Conserving Therapy versus Radical Mastectomy on Prognosis for Young Women With Breast Carcinoma. Cancer* **2004**; 100:688-93
237. Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlerstsen B, Nielsen KV, Schönau A, Overgaard J. *Amplification of HER2 and TOP2A and Deletion of TOP2A Genes in Breast Cancer Investigated by New FISH Probes. Acta Oncol* **2004**; 43:35-42
238. Christensen LH, Engholm G, Ceberg J, Hein S, Perfekt R, Tange UB, Andersson M, Mouridsen HT, Möller T, Storm HH. *Can the survival difference between breast cancer patients in Denmark and Sweden 1989 and 1994 be explained by pathoanatomical variables? - A population-based study. Eur J of Cancer* **2004**; 40:1233-43
239. Ejlerstsen B, Mouridsen HT, Langkjær ST, Andersen J, Sjöström J, Kjær M. *Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403). J of Clin Oncol* **2004**; 12:2313-20
240. Pedersen L, Gunnarsdóttir KA, Rasmussen BB, Møller S, Lanng C. *The prognostic influence of multifocality in breast cancer patients. The Breast* **2004**; 13:188-93
241. Tjønneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Møller S, Møller S. *Hormone Replacement Therapy in Relation to Breast Carcinoma Incidence Rate Ratios. Cancer* **2004**; 100:2328-37
242. Mouridsen HT, Brüner N. *Clinical Infrastructures to Support Proteomic Studies of Tissue and Fluids in Breast Cancer. Molecular & Cellular Proteomics* **2004**; 3:302-10
243. Olsen A, Knudsen KEB, Thomsen BL, Loft S, Stripp C, Overvad K, Møller S, Tjønneland A. *Plasma Enterolactone and Breast Cancer Incidence by Estrogen Receptor Status. Cancer Epidemiol Biomarkers Prev* **2004**; 13(12):2084-9.
244. Wohlfahrt J, Rank F, Kroman N, Melbye M. *A comparison of reproductive risk factors for CIS lesions and invasive breast cancer. Int. J. Cancer* **2004**; 108(5):750-3.
245. Nielsen TG, Olsen A, Christensen J, Overvad K, Tjønneland A. *Dietary Carbohydrate Intake Is Not Associated with the Breast Cancer Incidence Rate Ratio in Postmenopausal Danish Women. J. Nutr.* **2005**; 135:124-28.
246. Olsen AH, Njor SH, Vejborg I, Schwartz Walter, Dalgaard P, Jensen MB, Tange UB, Blichert-Toft M, Rank F, Mouridsen H, Lynge E. *Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ* **2005**.
247. Wohlfahrt J. *Pregnancy and Breast Cancer. ISBN 87-990962-1-8, Doctoral Thesis. University of Copenhagen: 2005.*

248. Cold C, Düring M, Ewertz M, Knoop A, Møller S. *Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG)*. *British Journal of Cancer* **2005**; 93:627-32.
249. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridse HT, Ejlertsen B. *Retrospective Analysis of Topoisomerase Iia Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group*. *J Clin Oncol* **2005**; 23:7483-90